Info: Read More
  • 中药标准品生产商,产品定制服务
  • 愈创甘油醚

    Guaifenesin

    愈创甘油醚
    产品编号 CFN90974
    CAS编号 93-14-1
    分子式 = 分子量 C10H14O4 = 198.2
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Phenols
    植物来源 The herbs of Guaiacum officinale.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    愈创甘油醚 CFN90974 93-14-1 10mg QQ客服:2159513211
    愈创甘油醚 CFN90974 93-14-1 20mg QQ客服:2159513211
    愈创甘油醚 CFN90974 93-14-1 50mg QQ客服:2159513211
    愈创甘油醚 CFN90974 93-14-1 100mg QQ客服:2159513211
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Lund University (Sweden)
  • Auburn University (USA)
  • University of Eastern Finland (Finland)
  • University of Helsinki (Finland)
  • University of Wuerzburg (Germany)
  • Periyar University (India)
  • Charles Sturt University (Denmark)
  • University of Malaya (Malaysia)
  • Leibniz-Institut für Pflanzenbiochemie (IPB) (Germany)
  • Universidade da Beira Interior (Germany)
  • Medical University of South Carolina (USA)
  • University of Illinois at Chicago (USA)
  • University of Indonesia (Indonesia)
  • University of Sao Paulo (Brazil)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Molecules 2021, 26(4),1092.
  • Revista Brasileira de Farmacognosia2021, 31:794-804.
  • Pol J Microbiol.2021, 70(1):117-130.
  • Molecules.2022, 27(2):451.
  • bioRxiv2021, 462065.
  • Front Plant Sci.2022, 12:811166.
  • Appl. Sci.2023, 13(17), 9653.
  • Applied Biological Chemistry2023, 66:42.
  • Front Pharmacol.2016, 7:460
  • Tropical Journal of Pharmaceutical Research 2021, 20(6):1165-1170.
  • Plant Physiol Biochem.2023, 203:108073.
  • J of the Society of Cosmetic Scientists of Korea2018, 44(4):407-417
  • Horticulture Research2022, uhac276.
  • Phytochem Anal.2013, 24(5):493-503
  • Int J Mol Sci.2021, 22(14):7324.
  • US20170000760 A12016, 42740
  • Nat Prod Commun.2014, 9(5):679-82
  • Nutrients.2019, 11(6):E1380
  • Molecules.2019, 24(9):E1719
  • J Herbmed Pharmacol.2018, 7(4):280-286
  • Appl. Sci. 2021, 11(17),7829
  • Mol Biol Rep.2022, doi: 10.1007
  • Toxicol Appl Pharmacol.2021, 427:115668.
  • ...
  • 生物活性
    Description: Guaifenesin is also a centrally acting skeletal muscle relaxant. Guaifenesin has antitussive effects, it can inhibit the cough-reflex sensitivity in acute viral cough, it is an expectorant commonly by thinning the mucus or phlegm in the lungs.
    In vivo:
    J Clin Pharmacol. 2015 Dec 3. doi: 10.1002/jcph.682.
    Guaifenesin Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 Years.[Pubmed: 26632082]

    METHODS AND RESULTS:
    This study characterized guaifenesin pharmacokinetics in children aged 2 to 17 years (n = 40) who received a single oral dose of guaifenesin (age-based doses of 100-400 mg) 2 hours after breakfast. Plasma samples were obtained before and for 8 hours after dosing and analyzed for guaifenesin using liquid chromatography-tandem mass spectrometry. Pharmacokinetic parameters were estimated using noncompartmental methods, relationships with age were assessed using linear regression, and dose proportionality was assessed on 95% confidence intervals. Based on the upper dose recommended in the monograph (for both children and adolescents), area under the curve from time zero to infinity and maximum plasma concentration both increased with age. However, when comparing the upper dose for children aged 2 to 11 years with the lower dose for adolescents aged 12 to 17 years, similar systemic exposure was observed. As expected due to increasing body size, oral clearance (CLo ) and terminal volume of distribution (Vz /F) increased with age. Due to a larger increase in Vz /F than CLo , an increase in terminal exponential half-life was also observed.
    CONCLUSIONS:
    Allometric scaling indicated no maturation-related changes in CLo and Vz /F.
    J Pain Res. 2017 Mar 21;10:669-678.
    Efficacy and safety of guaifenesin for upper back, neck, and shoulder pain: a Phase II proof-of-concept, multicenter, placebo-controlled, repeat-dose, parallel-group study.[Pubmed: 28356767]
    Guaifenesin, an over-the-counter (OTC) expectorant, has exhibited muscle relaxant effects preclinically and clinically. This proof-of-principle study explored whether OTC doses of guaifenesin can provide relief from acute upper back, neck, or shoulder muscle spasm and pain.
    METHODS AND RESULTS:
    This multicenter, placebo-controlled, repeat-dose, parallel study randomly assigned adults experiencing acute pain and muscle spasm in their upper back, neck, or shoulder to guaifenesin 600 or 1200 mg or matched placebo twice daily (BID) in a 2:2:1:1 ratio for 7 days. The primary end point was the change from baseline in muscle spasm relief, measured using an 11-point numeric rating scale (0=not present to 10=unbearable) recorded twice daily and averaged over the 7-day treatment period. Analyses were performed using a linear mixed model that included treatment as a fixed effect and site as a random effect. A total of 77 subjects were included in the 4 treatment groups. Least squares mean muscle spasm score over 7 days was 1.77 with guaifenesin 1200 mg, 1.42 with its matched placebo, 1.53 with guaifenesin 600 mg, and 1.74 with its matched placebo. Treatment with guaifenesin 1200 mg BID provided 25% greater reduction in mean muscle spasm over its matched placebo and 16% greater reduction than guaifenesin 600 mg BID. These differences were not statistically significant. Based on comparisons of absolute mean values, a consistent directional change in effect was observed, suggesting some benefit from placebo to lower-to-upper doses of guaifenesin with regard to muscle spasm, tension, pain, discomfort, and relaxation. No severe or serious adverse events were reported.
    CONCLUSIONS:
    Results suggest the potential for OTC dose of guaifenesin 1200 mg BID to provide symptomatic relief of upper back musculoskeletal pain and spasm. Confirmation of this preliminary result in a larger, adequately powered study is needed.
    Respir Med. 2009 Jun;103(6):902-6.
    Inhibition of cough-reflex sensitivity by benzonatate and guaifenesin in acute viral cough.[Pubmed: 19121573]
    Acute cough due to viral upper respiratory tract infection (URI) is the most common form of cough and accounts for tremendous expenditure on prescription and non-prescription cough products worldwide. However, few agents have been shown in properly conducted clinical trials to be effective for cough due to URI.
    METHODS AND RESULTS:
    The present study evaluated the effect of benzonatate 200mg (B), guaifenesin 600 mg (G), their combination (B+G), and placebo (P) on capsaicin-induced cough in 30 adult nonsmokers with acute URI. On 3 separate days within a 7-day period, 1h after ingesting randomly assigned study drug in a double-blind fashion, subjects underwent capsaicin cough challenge testing, which involved inhalation of incremental doubling concentrations of capsaicin until the concentration of capsaicin inducing 5 or more coughs (C(5)) was attained. Each subject received 3 of 4 possible study drugs. G (p=0.01) but not B (p=NS) inhibited cough-reflex sensitivity (log C(5)) relative to P. The combination of B+G suppressed capsaicin-induced cough to a greater degree than B alone (p<0.001) or G alone (p=0.008). The mechanism by which the combination of B+G causes a potentiation of antitussive effect remains to be elucidated.
    CONCLUSIONS:
    Our results suggest that B+G may be an effective therapy for acute cough due to the common cold (URI).
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 5.0454 mL 25.227 mL 50.4541 mL 100.9082 mL 126.1352 mL
    5 mM 1.0091 mL 5.0454 mL 10.0908 mL 20.1816 mL 25.227 mL
    10 mM 0.5045 mL 2.5227 mL 5.0454 mL 10.0908 mL 12.6135 mL
    50 mM 0.1009 mL 0.5045 mL 1.0091 mL 2.0182 mL 2.5227 mL
    100 mM 0.0505 mL 0.2523 mL 0.5045 mL 1.0091 mL 1.2614 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    间苯二酚; Resorcinol CFN99089 108-46-3 C6H6O2 = 110.1 20mg QQ客服:1413575084
    3-甲氧基苯酚; m-Methoxyphenol CFN99625 150-19-6 C7H8O2 = 124.1 20mg QQ客服:215959384
    熊果苷; 熊果甙; 对羟基苯-beta-D-吡喃葡糖苷; Arbutin CFN99550 497-76-7 C12H16O7 = 272.26 20mg QQ客服:215959384
    芝麻酚; Sesamol CFN90452 533-31-3 C7H6O3 = 138.12 20mg QQ客服:1413575084
    异它乔糖甙; Isotachioside CFN98398 31427-08-4 C13H18O8 = 302.3 5mg QQ客服:2159513211
    4'-羟基-2'-甲氧基苯酚1-O-beta-D-(6-O-紫丁香酰)吡喃葡萄糖苷; 4-Hydroxy-2-methoxyphenol 1-O-(6-O-syringoyl)glucoside CFN97527 945259-61-0 C22H26O12 = 482.4 5mg QQ客服:1457312923
    新化合物14; New compound 14 CFN95381 N/A C24H28O13 = 524.5 5mg QQ客服:2056216494
    它乔糖甙; Tachioside CFN99092 109194-60-7 C13H18O8 = 302.3 5mg QQ客服:2159513211
    3,4-二甲氧基苯酚; 3,4-Dimethoxyphenol CFN98027 2033-89-8 C8H10O3 = 154.2 20mg QQ客服:2159513211
    3,4-二甲氧基苯基-beta-D-葡萄糖苷; 3,4-Dimethoxyphenyl beta-D-glucoside CFN97405 84812-00-0 C14H20O8 = 316.3 5mg QQ客服:2056216494

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产